Acrux

New Product Launches Including Cone 75% Will Expand Market Presence

AnalystConsensusTarget

Not Invested

Consensus Narrative from 1 Analyst

Published

13 May 25

Updated

24 Jul 25

AnalystConsensusTarget's Fair Value

AU$0.09

81.1% undervalued

24 Jul

AU$0.017

-71.7%

-5.6%

Author's Valuation

AU$0.09

81.1% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$0.09

81.1% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

60.33%

Pharma revenue growth rate

1.11%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.48%

Calculation

AU$13.77m

Earnings '28

6.96x

PE Ratio '28

AU$95.84m

Market Cap '28

AU$95.84m

Market Cap '28

883.74m

No. shares '28

AU$0.11

Share Price '28

AU$0.11 Share Price '28

Discounted to 2025 @ 6.41% p.a.

AU$0.09

Fair Value '25